Characterisation of multidrug-resistant Ehrlich ascites tumour cells selected in vivo for resistance to etoposide

Biochemical Pharmacology

Volumn 60, Issue 3, 2000, Pages 353-361

  Nielsen, Dorte ^a   Maare, Christian ^a   Eriksen, Jens ^a   Litman, Thomas ^a   Friche, Ellen ^b   Skovsgaard, Torben ^a  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

^b Rigshospitalet   (Denmark)

Author keywords

Drug resistance; Etoposide; Multidrug resistance associated protein; Topoisomerase II; Tumour cell lines

Indexed keywords

ADENOSINE TRIPHOSPHATASE; DAUNORUBICIN; DNA TOPOISOMERASE (ATP HYDROLYSING); ETOPOSIDE; VANADIC ACID; VERAPAMIL; VINCRISTINE;

ARTICLE; DRUG ACCUMULATION; DRUG ANTAGONISM; DRUG MECHANISM; DRUG SENSITIVITY; EHRLICH ASCITES TUMOR; ENZYME ACTIVITY; GLYCOLYSIS; PRIORITY JOURNAL; STEADY STATE; TUMOR CELL CULTURE;

ADENOSINE TRIPHOSPHATASES; ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; ATP-BINDING CASSETTE TRANSPORTERS; BIOLOGICAL TRANSPORT; CARCINOMA, EHRLICH TUMOR; CELL SIZE; DAUNORUBICIN; DNA TOPOISOMERASES, TYPE II; DRUG RESISTANCE, MULTIPLE; DRUG RESISTANCE, NEOPLASM; ETOPOSIDE; IMMUNOASSAY; MICE; MULTIDRUG RESISTANCE-ASSOCIATED PROTEINS; P-GLYCOPROTEIN; TUMOR CELLS, CULTURED;

EID: 0034257195     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-2952(00)00338-5     Document Type: Article

References (35)

1. Gottesman M.M., Pastan I. Biochemistry of multidrug resistance mediated by the multidrug transporter. Annu Rev Biochem. 62:1993;385-427.
2. Cole S.P., Bhardwaj G., Gerlach J.H., Mackie J.E., Grant C.E., Almquist K.C., Stewart A.J., Kurz E.U., Duncan A.M., Deeley R.G. Overexpression of a transporter gene in a multidrug-resistant human lung cancer cell line. Science. 258:1992;1650-1653.
3. Krishnamachary N., Center M.S. The MRP gene associated with a non-P-glycoprotein multidrug resistance encodes a 190-kDa membrane bound glycoprotein. Cancer Res. 53:1993;3658-3661.
4. Mirski S.E., Gerlach J.H., Cole S.P. Multidrug resistance in a human small cell lung cancer cell line selected in adriamycin. Cancer Res. 47:1987;2594-2598.
5. Slovak M.L., Ho J.P., Bhardwaj G., Kurz E.U., Deeley R.G., Cole S.P. Localization of a novel multidrug resistance-associated gene in the HT1080/DR4 and H69AR human tumor cell lines. Cancer Res. 53:1993;3221-3225.
6. Zaman G.J., Versantvoort C.H., Smit J.J.M., Eijdems E.W., de Haas M., Smith A.J., Broxterman H.J., Mulder N.H., de Vries E.G., Baas F., Borst P. Analysis of the expression of MRP, the gene for a new putative transmembrane drug transporter, in human multidrug resistant lung cancer cell lines. Cancer Res. 53:1993;1747-1750.
7. Slapak C.A., Fracasso P.M., Martell R.L., Toppmeyer D.L., Lecerf J.-M., Levy S.B. Overexpression of the multidrug resistance-associated protein (MRP) gene in vincristine but not doxorubicin-selected multidrug-resistant murine erythroleukemia cells. Cancer Res. 54:1994;5607-5613.
8. Schneider E., Horton J.K., Yang C.-H., Nakagawa M., Cowan K.H. Multidrug resistance-associated protein gene overexpression and reduced drug sensitivity for topoisomerase II in a human breast carcinoma MCF7 cell line selected for etoposide resistance. Cancer Res. 54:1994;152-158.
9. Doyle L.A., Ross D.D., Ordonez J.V., Yang W., Gao Y., Tong Y., Belani C.P., Gutheil J.C. An etoposide-resistant lung cancer subline overexpresses the multidrug resistance-associated protein. Br J Cancer. 72:1995;535-542.
10. Sullivan D.M., Ross W.E. Resistance to inhibitors of DNA topoisomerases. Ozols R.F. Molecular and Clinical Advances in Anticancer Drug Resistance. 1991;57-99 Kluwer Academic, Boston.
11. Drake F.H., Hofmann G.A., Bartus H.F., Mattern M.R., Crooke S.T., Mirabelli C.K. Biochemical and pharmacological properties of p170 and p180 forms of topoisomerase II. Biochemistry. 28:1989;8154-8160.
12. Nielsen D., Maare C., Poulsen F., Lauridsen S.T., Skovsgaard T. Relationship between resistance, P-glycoprotein content and steady-state accumulation in five series of Ehrlich ascites tumour cell lines selected for resistance to daunorubicin. Cell Pharmacol. 1:1994;127-135.
13. Chomczynski P., Sacchi N. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem. 162:1987;156-159.
14. Danks M.K., Schmidt C.A., Cirtain M.C., Suttle D.P., Beck W.T. Altered catalytic activity of and DNA cleavage by DNA topoisomerase II from human leukemic cells selected for resistance to VM-26. Biochemistry. 27:1988;8861-8869.
15. Friche E., Danks M.K., Schmidt C.A., Beck W.T. Decreased DNA topoisomerase II in daunorubicin-resistant Ehrlich ascites tumor cells. Cancer Res. 51:1991;4213-4218.
16. Skovsgaard T. Mechanisms of resistance to daunorubicin in Ehrlich ascites tumor cells. Cancer Res. 38:1978;1785-1791.
17. Skovsgaard T. Carrier-mediated transport of daunorubicin, adriamycin, and rubidazone in Ehrlich ascites tumour cells. Biochem Pharmacol. 27:1978;1221-1227.
18. Nielsen D., Maare C., Skovsgaard T. Kinetics of daunorubicin transport in Ehrlich ascites tumor cells with different expression of P-glycoprotein. Influence of verapamil. Biochem Pharmacol. 47:1994;2125-2135.
19. Nielsen D., Maare C., Skovsgaard T. Influx of daunorubicin in multidrug resistant Ehrlich ascites tumor cells Correlation to expression of P-glycoprotein and efflux. Influence of verapamil . Biochem Pharmacol. 50:1995;443-450.
20. - permeabilities in Ehrlich ascites tumor cells. J Membr Biol. 78:1984;211-222.
21. Borgnia M.J., Eytan G.D., Assaraf Y.G. Competition of hydrophobic peptides, cytotoxic drugs, and chemosensitizers on a common P-glycoprotein pharmacophore as revealed by its ATPase activity. J Biol Chem. 271:1996;3163-3171.
22. Chifflet S., Torriglia A., Chiesa R., Tolosa A. A method for the determination of inorganic phosphate in the presence of labile organic phosphate and high concentrations of protein Application to lens ATPases . Anal Biochem. 168:1988;1-4.
23. Prost S. Mechanisms of resistance to topoisomerase poisons. Gen Pharmacol. 26:1995;1773-1784.
24. Cole S.P., Sparks K.E., Fraser K., Loe D.W., Grant C.E., Wilson G.M., Deeley R.G. Pharmacological characterization of multidrug resistant MRP-transfected human tumor cells. Cancer Res. 54:1994;5902-5910.
25. Zaman G.J., Flens M.J., van Leusden M.R., de Haas M., Mülder H.S., Lankelma J., Pinedo H.M., Scheper R.J., Baas F., Broxterman H.J., Borst P. The human multidrug resistance-associated protein MRP is a plasma membrane drug-efflux pump. Proc Natl Acad Sci USA. 91:1994;8822-8826.
26. Paul S., Breuninger L.M., Kruh G.D. ATP-dependent transport of lipophilic cytotoxic drugs by membrane vesicles prepared from MRP-overexpressing HL60/ADR cells. Biochemistry. 35:1996;14003-14011.
27. Gaj C.L., Anyanwutaku I., Chang Y.H., Cheng Y.-C. Decreased drug accumulation without increased efflux in a novel MRP-overexpressing multidrug-resistant cell line. Biochem Pharmacol. 55:1998;1199-1211.
28. Breuninger L.M., Paul S., Gaughan K., Miki T., Chan A., Aaronson S.A., Kruh G.D. Expression of multidrug resistance-associated protein in NIH/3T3 cells confers multidrug resistance associated with increased drug efflux and altered intracellular drug distribution. Cancer Res. 55:1995;5342-5347.
29. Barrand M.A., Rhodes T., Center M.S., Twentyman P.R. Chemosensitisation and drug accumulation effects of cyclosporin A, PSC-833 and verapamil in human MDR large cell lung cancer cells expressing a 190k membrane protein distinct from P-glycoprotein. Eur J Cancer. 29A:1993;408-415.
30. Mülder H.S., van Grondelle R., Westerhoff H.V., Lankelma J.A. A plasma membrane "vacuum cleaner" for daunorubicin in multidrug-resistant SW-1573 human non-small cell lung carcinoma cells. Eur J Biochem. 218:1993;871-882.
31. Flens M.J., Izquierdo M.A., Scheffer G.L., Fritz J.M., Meijer C.J., Scheper R.J., Zaman G.J.R. Immunochemical detection of the multidrug resistance-associated protein MRP in human multidrug-resistant tumor cells by monoclonal antibodies. Cancer Res. 54:1994;4557-4563.
32. Versantvoort C.H., Broxterman H.J., Pinedo H.M., de Vries E.G., Feller N., Kuiper C.M., Lankelma J. Energy-dependent processes involved in reduced drug accumulation in multidrug-resistant human lung cancer cell lines without P-glycoprotein expression. Cancer Res. 52:1992;17-23.
33. r 190,000 multidrug resistance protein (MRP) in drug-selected and transfected human tumor cells. Cancer Res. 55:1995;102-110.
34. Chang X.B., Hou Y.X., Riordan J.R. ATPase activity of purified multidrug resistance-associated protein. J Biol Chem. 272:1997;30962-30968.
35. 4 and structurally related conjugates. J Biol Chem. 269:1994;27807-27810.